PDCD1 and cancer: To avoid immune surveillance, cancer cells exploit checkpoint inhibition pathways, such as the PD1/PD-L1 (programmed cell death protein-1/programmed cell death ligand-1) pathway, which normally regulate the magnitude of immune reactions.